ReviewMolecular nutrition & food research2026
Peroxisomal Lipid Metabolism as a Therapeutic Target in Leukemia.
Review in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid delivery and metabolism profoundly shape cancer cell fate, energy balance, redox control, and therapy resistance. Peroxisomes regulate fatty acid oxidation (FAO) and oxidative homeostasis with growing relevance in hematologic malignancies. Recent studies show peroxisomal FAO (pFAO) is selectively elevated in acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), sustaining cancer cell survival under metabolic and therapeutic stress. Elevated ACOX1, ABCD1/2, CROT, and PEX5 expression underscores leukemia-specific peroxisomal vulnerability; their pharmacologic or genetic inhibition disrupts lipid homeostasis, induces very-long-chain fatty acid accumulation, and drives oxidative stress and lipotoxicity. This selectively kills leukemia cells while sparing normal progenitors. pFAO blockade synergizes with chemotherapy drugs such as venetoclax and cytarabine, enabling exploitation of metabolic vulnerabilities to improve therapeutic outcomes. Upstream, PPAR isoforms transcriptionally link lipid ligand sensing to peroxisomal gene expression, though their precise role in governing pFAO in leukemia remains undefined. Integrating solid tumor and leukemia insights, peroxisomes emerge as dynamic lipid-processing organelles coupling FAO, redox buffering, and inter-organelle exchange to cancer persistence. Targeting peroxisome-mediated lipid delivery offers a frontier for overcoming metabolic resilience and therapeutic resistance in leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.